Literature DB >> 30755697

Medical marijuana-an obesity problem or opportunity?

Frank L Greenway1, John P Kirwan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30755697      PMCID： PMC7157797          DOI： 10.1038/s41366-019-0334-z

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN： 0307-0565            Impact factor:   5.095


× No keyword cloud information.
  10 in total

1.  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Authors:  Adèle Thomas; Lesley A Stevenson; Kerrie N Wease; Martin R Price; Gemma Baillie; Ruth A Ross; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.

Authors:  Matthias Blüher; Stefan Engeli; Nora Klöting; Janin Berndt; Mathias Fasshauer; Sándor Bátkai; Pál Pacher; Michael R Schön; Jens Jordan; Michael Stumvoll
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

3.  Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish.

Authors:  F W Merkus
Journal:  Nature       Date:  1971-08-20       Impact factor: 49.962

4.  The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.

Authors:  R G Pertwee; A Thomas; L A Stevenson; R A Ross; S A Varvel; A H Lichtman; B R Martin; R K Razdan
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

5.  Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.

Authors:  Erin M Rock; Martin A Sticht; Marnie Duncan; Colin Stott; Linda A Parker
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

6.  Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.

Authors:  Gernot Riedel; Paola Fadda; Susan McKillop-Smith; Roger G Pertwee; Bettina Platt; Lianne Robinson
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

7.  Rimonabant: From RIO to Ban.

Authors:  Amir H Sam; Victoria Salem; Mohammad A Ghatei
Journal:  J Obes       Date:  2011-07-06

8.  Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.

Authors:  Luke Tudge; Clare Williams; Philip J Cowen; Ciara McCabe
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-25       Impact factor: 5.176

9.  Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Authors:  Khalid A Jadoon; Stuart H Ratcliffe; David A Barrett; E Louise Thomas; Colin Stott; Jimmy D Bell; Saoirse E O'Sullivan; Garry D Tan
Journal:  Diabetes Care       Date:  2016-08-29       Impact factor: 19.112

10.  The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

Authors:  E T Wargent; M S Zaibi; C Silvestri; D C Hislop; C J Stocker; C G Stott; G W Guy; M Duncan; V Di Marzo; M A Cawthorne
Journal:  Nutr Diabetes       Date:  2013-05-27       Impact factor: 5.097
  10 in total
  1 in total

Review 1.  Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target.

Authors:  Eulla Keimili Fernandes Ferreira Cavalheiro; Ana Beatriz Costa; Daniéle Hendler Salla; Mariella Reinol da Silva; Talita Farias Mendes; Larissa Espindola da Silva; Cristini da Rosa Turatti; Rafael Mariano de Bitencourt; Gislaine Tezza Rezin
Journal:  Cannabis Cannabinoid Res       Date:  2021-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.